First Liver Cancer Patient Treated With BTG’s LC Bead Lumi Supported by Philips’ Live Image-Guidance Technology
February 3, 2016—BTG plc and Royal Philips announced that the first liver cancer patient was treated with BTG’s LC Bead Lumi in conjunction with Philips’ live image-guidance technology to target a hypervascular tumor with the goal to block blood flow and achieve tumor necrosis.
The treatment signals the next stage in commercializing next-generation embolic beads, which can be visualized during interventional procedures. The US Food and Drug Administration cleared the LC Bead Lumi for clinical use in the United States in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead.
The LC Bead Lumi is a radiopaque embolic bead cleared for the embolization of hypervascular tumors and arteriovenous malformations. LC Bead Lumi provides visible confirmation of bead location during arteriovenous malformation procedures, and the device’s lasting radiopacity allows it to be visible in follow-up scans.
BTG and Philips will showcase their technology at CIO 2016, the Symposium on Clinical Interventional Oncology, being held February 6–7 in conjunction with ISET 2016, the International Symposium on Endovascular Therapies on February 6–10 at The Diplomat Hotel in Hollywood, Florida.
According to the companies, LC Bead Lumi’s radiopacity technology (developed in collaboration with Philips) enables real-time visualization of bead location during embolization, allowing physicians to evaluate the completeness of tumor treatment and endpoint determination. The combined use of the devices allows physicians to see, rather than assume, the location of the bead for accurate delivery of treatment.
In the companies’ announcement, Bradford Wood, MD, Director of the National Institutes of Health Center for Interventional Oncology and Chief of Interventional Radiology, commented, “The aim with this new radiopaque embolic bead and visualization technology is to provide clinicians like me the ability to make real-time adjustments while conducting the embolization procedure, so that we can optimize patient’s treatment and hopefully improve targeting accuracy. It is reassuring for the clinician and the patient to know that the treatment was delivered exactly where it was aimed, and where it was needed.”
Dr. Wood continued, “Treating the first patient using LC Bead Lumi in combination with dedicated Philips two-dimensional x-ray and three-dimensional cone-beam computed tomography image guidance is a milestone in our public-private partnership with both of our industry research partners. The imaging of the beads during this first procedure was exquisite and provided valuable information.”